State-of-the-art Review: Allogeneic Stem Cell Transplantation for Myelofibrosis in 2019

Overview

Journal Haematologica

Specialty Hematology

Date 2019 Mar 16

PMID 30872371

Citations 25

Authors

Donal P McLornan

Ibrahim Yakoub-Agha

Marie Robin

Yves Chalandon

Claire N Harrison

Nicolaus Kroger

Affiliations

Soon will be listed here.

Abstract

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical course and therapeutic response. In this timely review, we provide an up-to-date synopsis of current transplantation recommendations, discuss usage of JAK inhibitors before and after transplantation, examine donor selection and compare conditioning platforms. Moreover, we discuss emerging data concerning the impact of the myelofibrosis mutational landscape on transplantation outcome, peritransplant management of splenomegaly, poor graft function and prevention/management of relapse.

Citing Articles

Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations.

Carturan A, More S, Poloni A, Rupoli S, Morsia E Cancers (Basel). 2024; 16(23).

PMID: 39682299 PMC: 11640548. DOI: 10.3390/cancers16234113.

Myelofibrosis and allogeneic transplantation: critical points and challenges.

Ranalli P, Natale A, Guardalupi F, Santarone S, Canto C, La Barba G Front Oncol. 2024; 14:1396435.

PMID: 38966064 PMC: 11222377. DOI: 10.3389/fonc.2024.1396435.

Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.

Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson K Bone Marrow Transplant. 2024; 59(7):928-935.

PMID: 38491198 DOI: 10.1038/s41409-024-02269-4.

Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.

Gill H, Leung G, Ooi M, Teo W, Wong C, Choi C Clin Exp Med. 2023; 23(8):4199-4217.

PMID: 37747591 DOI: 10.1007/s10238-023-01189-9.

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide.

Trunk A, Patel S, Prchal J, Sborov D, Zander A, Lee C Leuk Res Rep. 2023; 20:100388.

PMID: 37701906 PMC: 10493243. DOI: 10.1016/j.lrr.2023.100388.

References

Scott B, Gooley T, Sorror M, Rezvani A, Linenberger M, Grim J . The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012; 119(11):2657-64. PMC: 3311279. DOI: 10.1182/blood-2011-08-372904. View

Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I . Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transplant. 2017; 52(11):1526-1529. DOI: 10.1038/bmt.2017.157. View

Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D . Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood. 2010; 116(18):3572-81. DOI: 10.1182/blood-2009-12-260588. View

Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S . DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2010; 29(4):392-7. DOI: 10.1200/JCO.2010.32.2446. View

Tefferi A, Mudireddy M, Mannelli F, Begna K, Patnaik M, Hanson C . Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018; 32(5):1200-1210. PMC: 5940634. DOI: 10.1038/s41375-018-0019-y. View

Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A . Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia. 2014; 28(7):1552-5. DOI: 10.1038/leu.2014.66. View

Raj K, Eikema D, McLornan D, Olavarria E, Blok H, Bregante S . Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018; 25(3):522-528. DOI: 10.1016/j.bbmt.2018.10.017. View

Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay J . Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2010; 152(3):331-9. DOI: 10.1111/j.1365-2141.2010.08417.x. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

10.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10):2062-8. PMC: 4854652. DOI: 10.1038/leu.2015.212. View

11.

Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T . Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol. 2018; 101(3):305-317. DOI: 10.1111/ejh.13099. View

12.

Kroger N, Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F . Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018; 24(10):2152-2156. DOI: 10.1016/j.bbmt.2018.05.023. View

13.

Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B . Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2009; 16(3):358-67. PMC: 2908949. DOI: 10.1016/j.bbmt.2009.10.025. View

14.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

15.

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

16.

Lasho T, Jimma T, Finke C, Patnaik M, Hanson C, Ketterling R . SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012; 120(20):4168-71. DOI: 10.1182/blood-2012-05-429696. View

17.

Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M . Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood. 2010; 116(4):649-52. DOI: 10.1182/blood-2009-11-252601. View

18.

Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M . EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011; 118(19):5227-34. DOI: 10.1182/blood-2011-06-363424. View

19.

Kerbauy D, Gooley T, Sale G, Flowers M, Doney K, Georges G . Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007; 13(3):355-65. DOI: 10.1016/j.bbmt.2006.11.004. View

20.

Stubig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T . JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014; 28(8):1736-8. DOI: 10.1038/leu.2014.86. View